相关实验视频
Updated: May 10, 2026

11:34
Scattering And Absorption of Light in Planetary Regoliths
Published on: July 1, 2019
10.9K
多发性硬化症在老年人中的临床特征在芬兰第三级医疗中心
Iiro Korhonen1, Ilkka Rauma2, Kimi Ahtinen1
1Tampere University, Faculty of Medicine and Health Technology, Tampere, Finland.
Clinical neurology and neurosurgery
|October 9, 2025
概括
患有多发性硬化症 (OAwMS) 的老年人经常患有进展性疾病和重大残疾. 65岁以后的复发很少发生,这表明人们应该专注于OAwMS的多学科护理和症状管理.
科学领域:
- 神经学 神经学
- 老年病的医生 老年病的医生
- 临床研究 临床研究
背景情况:
- 关于患有多发性硬化症 (OAwMS) 的老年人 (65岁以上) 临床特征的数据有限.
- 了解这种人口群体的疾病表现和残疾进展对于有效管理至关重要.
研究的目的:
- 调查OAwMS的临床表现,疾病修饰疗法 (DMT) 的使用和神经障碍.
- 确定多发性硬化症的老年人中的疾病活动和残疾如何表现.
- 评估早期使用DMT是否与晚年残疾减少有关.
主要方法:
- 在坦佩雷大学医院 (TUH) 接受治疗的OAwMS的回顾性分析,使用芬兰MS注册表的数据.
- 提取和分析人口和临床数据,包括扩展残疾状况量表 (EDSS) 评分.
主要成果:
- 在264个确定的OAwMS中,71.6%的MS进展,只有23.5%曾经使用过DMT.
- 65岁以后的复发不常见 (9.2%的患者先前患有复发性复发性MS).
- 65岁后EDSS中位数为6.5,表明明显的运动障碍,其中71.9%显示残疾恶化.
结论:
- 大多数OAwMS经历了进展性疾病和明显的残疾,在65岁后很少复发.
- 对OAwMS的治疗应优先考虑多学科的方法,包括康复和症状护理.
- 在患有多发性硬化症的老年人中,DMT的作用和疗效需要进一步研究,特别是在活跃的疾病病例中.
相关概念视频
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Absorption
As individuals age, their body's physiology evolves, affecting drug pharmacokinetics. The most apparent changes occur in the gastrointestinal tract, where an increase in gastric pH, a delay in gastric emptying, and a reduction in gastrointestinal motility are observed. Remarkably, these changes do not substantially modify the absorption of orally administered drugs, particularly those absorbed via passive diffusion.Transdermal drug delivery emerges as a highly viable method for older adults due...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Metabolism
Geriatric patients show significant variation in how their bodies process medications, which can change how effective and safe treatments are. The liver is the primary organ where drug metabolism occurs, involving two main types of chemical reactions: phase I and II. Phase I metabolism is driven by the cytochrome P450 enzyme system, which includes key types such as CYP3A, CYP2D6, and CYP2C9. Research indicates that while aging doesn't notably alter the levels or activity of these enzymes, it...
Pharmacokinetics in Geriatric Patients: Effect of Age on Drug Excretion
In geriatric patients, renal physiology undergoes significant changes, including diminished renal blood flow and a lower glomerular filtration rate (GFR), leading to alterations in medication clearance. Drugs such as aminoglycoside antibiotics, lithium, and digoxin, which rely on glomerular filtration for removal from the body, particularly impact pharmacokinetics. These drugs tend to have slower clearance rates in older adults, necessitating careful dosage considerations.Evaluation of renal...
Pharmacodynamics in Geriatric Patients: Effects of Age
Age-related pharmacokinetic changes are extensively documented, but understanding age-related pharmacodynamic alterations is relatively limited. This knowledge gap can be partly attributed to the complexity of developing appropriate measures of drug responses compared to bioanalytical methods for determining drug concentrations.Most information regarding age-related differences in human pharmacodynamics originates from cross-sectional studies. However, these studies assume that observed mean...
Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
Alzheimer Disease l: Introduction
Alzheimer disease is a chronic, progressive, and irreversible neurodegenerative disorder and the most common cause of dementia in older adults. It leads to gradual neuronal loss, causing cognitive decline, behavioral changes, and loss of functional independence.Risk Factors and EtiologyThe disease is multifactorial. Age is the strongest risk factor, with prevalence doubling every 5 years after age 65. Genetic factors include mutations in genes such as APP, PSEN1, and PSEN2, which are associated...